Get 40% Off
🎁 Free Gift Friday: Copy Legendary Investors' Portfolios in One ClickCopy for Free

Why CorMedix Are Trading Lower By 22%; Here Are 20 Stocks Moving Premarket

Published 29/06/2023, 13:18
© Reuters.  Why CorMedix Are Trading Lower By 22%; Here Are 20 Stocks Moving Premarket

Benzinga - Gainers

  • Eco Wave Power Global AB (NASDAQ: WAVE) shares surged 123% to $3.48 in pre-market trading after dropping over 8% on Wednesday.
  • Kintara Therapeutics, Inc. (NASDAQ: KTRA) shares gained 33.1% to $3.98 in pre-market trading after the company secured $2.0 million National Institutes of Health SBIR grant to support clinical development of REM-001.
  • Fangdd Network Group Ltd. (NASDAQ: DUO) shares rose 21.7% to $0.9367 in pre-market trading after dropping 11% on Wednesday. FangDD Network Group recently received Nasdaq notice regarding minimum bid price requirements.
  • BlackBerry Limited (NYSE: BB) shares rose 18.5% to $5.94 in pre-market trading after the company reported better-than-expected fiscal first-quarter results.
  • Emerson Radio Corp. (NYSE: MSN) shares gained 18.5% to $0.64 in pre-market trading.
  • Akso Health Group (NASDAQ: AHG) shares climbed 18.2% to $0.39 in pre-market trading after gaining around 5% on Wednesday.
  • Better Choice Company Inc. (NYSE: BTTR) rose 16.7% to $0.2690 in pre-market trading after declining around 8% on Wednesday. Better Choice recently announced a $5 million investment from Alphia, establishing a direct manucafturing relationship.
  • AIM ImmunoTech Inc. (NYSE: AIM) gained 15.8% to $0.6830 in pre-market trading after gaining around 5% on Wednesday. AIM ImmunoTech recently announced publication of findings from a pre-clinical study evaluating Ampligen in the treatment of pancreatic cancer in the American Journal of Cancer Research.
  • ZIVO Bioscience, Inc. (NASDAQ: ZIVO) rose 14.5% to $2.69 in pre-market trading after declining over 3% on Wednesday.
  • Shapeways Holdings, Inc. (NYSE: SHPW) gained 11.9% to $3.30 in pre-market trading after the company announced securing two new Tier 1 supplier contracts.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
Losers
  • CorMedix Inc. (NASDAQ: CRMD) fell 21.6% to $3.97 in pre-market trading after the company reported pricing of $40 million public offering of common stock and pre-funded warrants.
  • iMedia Brands, Inc. (NASDAQ: IMBI) fell 14.1% to $0.1656 in pre-market trading after jumping 20% on Wednesday.
  • Novan, Inc. (NASDAQ: NOVN) fell 13.4% to $0.3971 in pre-market after gaining over 12% on Wednesday.
  • Knightscope, Inc. (NASDAQ: KSCP) fell 11.4% to $0.6201 in pre-market trading after jumping 52% on Wednesday. The company's CEO made comments about 2023 projections on the Stock Day podcast.
  • Minerva Neurosciences, Inc. (NASDAQ: NERV) fell 10.1% to $9.16 in pre-market trading. Minerva Neurosciences shares jumped over 69% on Wednesday after the company announced a $20 million private placement priced at a premium to the market.
  • Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) shares dropped 10% to $5.16 in pre-market trading after the company reported a $75 million proposed public offering of common stock.
  • Surgalign Holdings, Inc. (NASDAQ: SRGA) shares dropped 10% to $0.27 in pre-market trading after gaining 11% on Wednesday. Surgalign Holdings’ subsidiary Holo Surgical was granted European Patent Number EP3751516 titled "Autonomous Multidimensional Segmentation Of Anatomical Structures On Three-Dimensional Medical Imaging."
  • Centogene N.V. (NASDAQ: CNTG) fell 8.9% to $1.44 in pre-market trading after jumping 34% on Wednesday. CENTOGENE and Lifera recently formed a Saudi Arabian joint venture.
  • Appreciate Holdings, Inc. (NASDAQ: SFR) fell 8.1% to $0.3739 in pre-market trading after gaining 7% on Wednesday.
  • Jaguar Health, Inc. (NASDAQ: JAGX) shares fell 7% to $0.4820 in pre-market trading. Napo Pharmaceuticals, a Jaguar Health Company, submitted investigational new drug application to the FDA for microvillus inclusion disease.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Now Read This: Investor Optimism Improves After Nasdaq Settles Higher

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.